Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 11:13:1.
doi: 10.3389/fnmol.2020.00001. eCollection 2020.

Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics

Affiliations

Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics

Pamela Barraza-Flores et al. Front Mol Neurosci. .

Abstract

Laminin-α2-related congenital muscular dystrophy (LAMA2-CMD) is a devastating neuromuscular disease caused by mutations in the LAMA2 gene. These mutations result in the complete absence or truncated expression of the laminin-α2 chain. The α2-chain is a major component of the laminin-211 and laminin-221 isoforms, the predominant laminin isoforms in healthy adult skeletal muscle. Mutations in this chain result in progressive skeletal muscle degeneration as early as neonatally. Laminin-211/221 is a ligand for muscle cell receptors integrin-α7β1 and α-dystroglycan. LAMA2 mutations are correlated with integrin-α7β1 disruption in skeletal muscle. In this review, we will summarize laminin-211/221 interactions with integrin-α7β1 in LAMA2-CMD muscle. Additionally, we will summarize recent developments using upregulation of laminin-111 in the sarcolemma of laminin-α2-deficient muscle. We will discuss potential mechanisms of action by which laminin-111 is able to prevent myopathy. These published studies demonstrate that laminin-111 is a disease modifier of LAMA2-CMD through different methods of delivery. Together, these studies show the potential for laminin-111 therapy as a novel paradigm for the treatment of LAMA2-CMD.

Keywords: LAMA2-CMD; Laminin; muscle; muscular dystrophy; therapeutic; α7 integrin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Molecular model in unaffected and laminin-α2-deficient patient muscle. (A) Laminin 211/221 heterotrimeric proteins bind through their N-terminal domain to the collagen-IV-rich basal lamina and through their C-terminal domain to muscle cell receptors heterodimers integrin-α7β1 and αβ-dystroglycan protein complexes. (B) In LAMA2-CMD, laminins are unable to bind to collagen-IV and/or integrin-α7β1 and α-dystroglycan protein complexes disrupting communication between the basal and muscle cell membrane.
Figure 2
Figure 2
Integrin-α7β1 protein complex is disrupted in laminin-α2-deficient muscle. (A) Decreased detection of integrin-α7β1 in the muscle sarcolemma in laminin-α2-truncated muscle. (B) Rescued expression of integrin-α7β1 in the muscle sarcolemma by expression of laminin-111 in laminin-α2-deficient muscle.

References

    1. Accorsi A., Mehuron T., Kumar A., Rhee Y., Girgenrath M. (2015). Integrin dysregulation as a possible driver of matrix remodeling in laminin-deficient congenital muscular dystrophy (MDC1A). J. Neuromuscul. Dis. 2, 51–61. 10.3233/jnd-140042 - DOI - PubMed
    1. Barraza-Flores P., Fontelonga T. M., Wuebbles R. D., Hermann H. J., Nunes A. M., Kornegay J. N., et al. . (2019). Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of duchenne muscular dystrophy. Hum. Mol. Genet. 28, 2686–2695. 10.1093/hmg/ddz086 - DOI - PMC - PubMed
    1. Belkin A. M., Retta S. F., Pletjushkina O. Y., Balzac F., Silengo L., Fassler R., et al. . (1997). Muscle B1D integrin reinforces the cytoskeleton-matrix link: modulation of integrin adhesive function by alternative splicing. J. Cell Biol. 139, 1583–1595. 10.1083/jcb.139.6.1583 - DOI - PMC - PubMed
    1. Boppart M. D., Mahmassani Z. S. (2019). Integrin signaling: linking mechanical stimulation to skeletal muscle hypertrophy. Am. J. Physiol. Cell Physiol. 317, C629–C641. 10.1152/ajpcell.00009.2019 - DOI - PMC - PubMed
    1. Burkin D. J., Kaufman S. J. (1999). The α7β1 integrin in muscle development and disease. Cell Tissue Res. 296, 183–190. 10.1007/s004410051279 - DOI - PubMed